ASCO GI: Data from Adjuvant CRC Study Perplexing
SAN FRANCISCO (MedPage Today) — Activity in advanced colorectal cancer failed to translate into a survival benefit in the adjuvant setting for bevacizumab (Avastin), results of a large European trial showed.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com